SOP for device study approvals – Clinical Research Made Simple https://www.clinicalstudies.in Trusted Resource for Clinical Trials, Protocols & Progress Wed, 06 Aug 2025 15:29:57 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.1 SOP for Device and IDE Submissions https://www.clinicalstudies.in/sop-for-device-and-ide-submissions/ Wed, 06 Aug 2025 15:29:57 +0000 ]]> https://www.clinicalstudies.in/sop-for-device-and-ide-submissions/ Read More “SOP for Device and IDE Submissions” »

]]>
SOP for Device and IDE Submissions

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Device-and-IDE-Submissions”
},
“headline”: “SOP for Device and Investigational Device Exemption (IDE) Submissions”,
“description”: “This SOP provides a step-by-step regulatory-compliant process for preparing and submitting device/IDE applications in clinical research, aligned with FDA, EMA, CDSCO, WHO, and ICH GCP guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Device and IDE Submissions in Clinical Trials

Department Clinical Research
SOP No. CR/DEV/005/2025
Supersedes NA
Page No. 1 of 22
Issue Date 26/08/2025
Effective Date 01/09/2025
Review Date 01/09/2026

Purpose

The purpose of this SOP is to define standardized procedures for preparing, reviewing, submitting, and tracking clinical trial submissions for medical devices, including Investigational Device Exemptions (IDE). It ensures compliance with FDA 21 CFR Part 812, EMA Medical Device Regulation (MDR 2017/745), CDSCO Medical Device Rules (2017), WHO, and ICH GCP guidelines.

Scope

This SOP applies to regulatory affairs, investigators, sponsors, and quality assurance personnel involved in device-related clinical trials. It covers IDE submissions, device clinical trial approvals, ethics committee submissions, and ongoing regulatory reporting for investigational devices.

Responsibilities

  • Principal Investigator (PI): Ensures scientific justification for device use and provides clinical data.
  • Regulatory Affairs Manager: Compiles and submits IDE/device dossiers to regulatory authorities.
  • Clinical Research Associate (CRA): Supports documentation, protocol adherence, and monitoring.
  • Quality Assurance Officer: Ensures compliance of device dossier with SOPs and regulations.
  • Head of Clinical Research: Approves submissions prior to dispatch.

Accountability

The Regulatory Affairs Head is accountable for ensuring that all IDE/device submissions comply with regulatory requirements and timelines. Non-compliance can lead to clinical hold, rejection, or trial suspension.

Procedure

1. Pre-Submission Preparation
Identify whether device requires IDE submission or local regulatory equivalent.
Collect technical documentation including device description, design dossier, preclinical/bench testing data, and prior clinical experience if available.
Prepare Investigational Plan as per FDA 21 CFR Part 812 or MDR Annex XV.

2. Compilation of Device Submission Dossier
Include Investigator’s Brochure, clinical protocol, informed consent forms, device labeling, and instructions for use.
Provide risk assessment and justification for human use.
Ensure device accountability and traceability procedures are described.

3. Review and Approval
QA reviews dossier against regulatory submission checklists.
Obtain PI and sponsor approval before finalization.

4. Submission to Regulatory Authority
Submit IDE application to FDA (Form FDA 1571/1572 as applicable) or equivalent forms for EMA/CDSCO.
Ensure electronic submission format (e.g., eCopy for FDA, online portal for CDSCO).
Obtain acknowledgment and maintain communication log.

5. Ethics Committee/IRB Approval
Submit device dossier, risk-benefit assessment, and informed consent documents to EC/IRB.
Retain signed EC approval letters in Trial Master File.

6. Post-Approval Compliance
Ensure submission of progress reports, annual IDE reports, and safety updates.
Report Serious Adverse Device Effects (SADEs) within 10 working days to regulatory authorities.
Notify regulatory authorities and EC/IRB of protocol amendments.

7. Documentation and Archiving
Maintain device submission records, acknowledgment receipts, and approval letters in TMF.
Retain documents for minimum of 10 years as per MDR or 5 years post trial completion.

Abbreviations

  • SOP: Standard Operating Procedure
  • IDE: Investigational Device Exemption
  • PI: Principal Investigator
  • CRA: Clinical Research Associate
  • QA: Quality Assurance
  • EC/IRB: Ethics Committee/Institutional Review Board
  • SADE: Serious Adverse Device Effect
  • TMF: Trial Master File

Documents

  1. Device Submission Checklist (Annexure-1)
  2. Device Submission Tracker (Annexure-2)
  3. Device Communication Log (Annexure-3)

References

  • FDA 21 CFR Part 812 – Investigational Device Exemptions
  • EU MDR 2017/745 – Medical Device Regulation
  • CDSCO Medical Device Rules (2017)
  • ICH E6(R2) – Good Clinical Practice
  • WHO Guidance on Clinical Evaluation of Devices

Version: 1.0

Approval Section

Prepared By Rajesh Kumar, Regulatory Affairs Specialist
Checked By Sunita Reddy, QA Officer
Approved By Dr. Anil Sharma, Head of Clinical Research

Annexures

Annexure-1: Device Submission Checklist

Document Included (Yes/No) Remarks
Device Description Yes Finalized version
Bench Testing Data Yes Included with dossier
Risk Assessment Yes Reviewed by QA

Annexure-2: Device Submission Tracker

Submission Type Date Submitted Authority Status Remarks
IDE 05/09/2025 US FDA Pending Acknowledgment received
Device Clinical Trial 10/09/2025 CDSCO In review Safety data requested

Annexure-3: Device Communication Log

Date Authority Query Response Responsible Person
15/09/2025 EMA Clarify labeling details Submitted revised IFU Rajesh Kumar

Revision History

Revision Date Revision No. Revision Details Reason for Revision Approved By
26/08/2025 00 Initial version New SOP creation Head, Clinical Research

For more SOPs visit: Pharma SOP

]]>